RT Journal Article
SR Electronic
T1 Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e1178
DO 10.1212/NXI.0000000000001178
VO 9
IS 4
A1 Virginia Palomares Cabeza
A1 Laura Y.L. Kummer
A1 Luuk Wieske
A1 Ruth R. Hagen
A1 Mariel Duurland
A1 Veronique A.L. Konijn
A1 Koos P.J. van Dam
A1 Eileen W. Stalman
A1 Carolien E. van de Sandt
A1 Laura Boekel
A1 Niels J.M. Verstegen
A1 Maurice Steenhuis
A1 Theo Rispens
A1 Sander W. Tas
A1 Gertjan Wolbink
A1 Joep Killestein
A1 Taco W. Kuijpers
A1 S. Marieke van Ham
A1 Filip Eftimov
A1 Anja ten Brinke
A1 Zoé L.E. van Kempen
A1 ,
YR 2022
UL http://nn.neurology.org/content/9/4/e1178.abstract
AB Objectives To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod.Methods This is a substudy of a prospective multicenter study on SARS-CoV-2 vaccination in patients with immune-mediated diseases. Patients with MS treated with ocrelizumab, fingolimod, and no disease-modifying therapies and healthy controls were included. The number of interferon (IFN)-γ secreting SARS-CoV-2–specific T cells at multiple time points before and after 3 SARS-CoV-2 vaccinations were evaluated.Results In ocrelizumab-treated patients (N = 24), IFN-γ–producing SARS-CoV-2–specific T-cell responses were induced after 2 vaccinations with median levels comparable to healthy controls (N = 12) and patients with MS without disease-modifying therapies (N = 10). A third vaccination in ocrelizumab-treated patients (N = 8) boosted T-cell responses that had declined after the second vaccination, but did not lead to higher overall T-cell responses as compared to immediately after a second vaccination. In fingolimod-treated patients, no SARS-CoV-2–specific T cells were detected after second (N = 12) and third (N = 9) vaccinations.Discussion In ocrelizumab-treated patients with MS, a third SARS-CoV-2 vaccination had no additive effect on the maximal T-cell response but did induce a boost response. In fingolimod-treated patients, no T-cell responses could be detected following both a second and third SARS-CoV-2 vaccination.